Concepts (182)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Plasmodium falciparum | 31 | 2022 | 254 | 4.850 |
Why?
|
| Malaria, Falciparum | 23 | 2022 | 232 | 3.350 |
Why?
|
| Antimalarials | 15 | 2021 | 125 | 2.030 |
Why?
|
| Polymorphism, Single Nucleotide | 14 | 2022 | 494 | 1.930 |
Why?
|
| Malaria | 9 | 2022 | 156 | 1.690 |
Why?
|
| DNA, Protozoan | 7 | 2020 | 50 | 1.330 |
Why?
|
| Drug Resistance | 14 | 2021 | 153 | 1.120 |
Why?
|
| Senegal | 15 | 2022 | 17 | 0.870 |
Why?
|
| Mass Drug Administration | 2 | 2020 | 13 | 0.810 |
Why?
|
| Plasmodium vivax | 3 | 2020 | 51 | 0.750 |
Why?
|
| Genotype | 12 | 2022 | 657 | 0.740 |
Why?
|
| Protozoan Proteins | 9 | 2020 | 132 | 0.720 |
Why?
|
| Genotyping Techniques | 3 | 2020 | 21 | 0.660 |
Why?
|
| Communicable Diseases, Imported | 1 | 2020 | 2 | 0.660 |
Why?
|
| Plasmodium ovale | 2 | 2017 | 10 | 0.640 |
Why?
|
| Genetic Variation | 6 | 2020 | 389 | 0.610 |
Why?
|
| Artemisinins | 6 | 2020 | 42 | 0.580 |
Why?
|
| Genetics, Population | 2 | 2018 | 43 | 0.580 |
Why?
|
| DNA Barcoding, Taxonomic | 8 | 2020 | 10 | 0.540 |
Why?
|
| Epidemiological Monitoring | 3 | 2020 | 32 | 0.520 |
Why?
|
| Plasmodium malariae | 1 | 2017 | 6 | 0.510 |
Why?
|
| Tetrahydrofolate Dehydrogenase | 3 | 2021 | 22 | 0.460 |
Why?
|
| Plasmodium | 4 | 2018 | 33 | 0.400 |
Why?
|
| Malaria, Vivax | 3 | 2020 | 53 | 0.390 |
Why?
|
| Genomics | 3 | 2022 | 383 | 0.300 |
Why?
|
| Dihydropteroate Synthase | 2 | 2020 | 6 | 0.300 |
Why?
|
| DNA Fingerprinting | 1 | 2008 | 7 | 0.290 |
Why?
|
| Adaptation, Biological | 2 | 2021 | 19 | 0.290 |
Why?
|
| Microarray Analysis | 1 | 2008 | 64 | 0.280 |
Why?
|
| Child | 10 | 2022 | 4554 | 0.280 |
Why?
|
| Child, Preschool | 9 | 2022 | 2042 | 0.270 |
Why?
|
| Genome, Protozoan | 3 | 2018 | 14 | 0.250 |
Why?
|
| Selection, Genetic | 3 | 2019 | 90 | 0.240 |
Why?
|
| Prevalence | 5 | 2017 | 1431 | 0.230 |
Why?
|
| Chloroquine | 3 | 2017 | 56 | 0.230 |
Why?
|
| Disease Eradication | 3 | 2020 | 5 | 0.230 |
Why?
|
| Sensitivity and Specificity | 3 | 2019 | 1159 | 0.230 |
Why?
|
| Models, Genetic | 2 | 2017 | 265 | 0.220 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2020 | 493 | 0.210 |
Why?
|
| Transgenes | 1 | 2025 | 202 | 0.210 |
Why?
|
| Pyrimethamine | 2 | 2021 | 20 | 0.210 |
Why?
|
| Humans | 28 | 2024 | 64768 | 0.210 |
Why?
|
| Zambia | 2 | 2020 | 19 | 0.200 |
Why?
|
| Sequence Analysis, RNA | 1 | 2024 | 180 | 0.200 |
Why?
|
| Protein Biosynthesis | 1 | 2025 | 331 | 0.190 |
Why?
|
| Adolescent | 9 | 2022 | 6247 | 0.180 |
Why?
|
| Parasitemia | 2 | 2019 | 49 | 0.180 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2024 | 309 | 0.180 |
Why?
|
| RNA, Messenger | 2 | 2025 | 1574 | 0.180 |
Why?
|
| Gene Expression Profiling | 1 | 2025 | 791 | 0.170 |
Why?
|
| Base Sequence | 3 | 2019 | 1329 | 0.170 |
Why?
|
| Folic Acid Antagonists | 1 | 2021 | 8 | 0.170 |
Why?
|
| Transcription, Genetic | 1 | 2025 | 905 | 0.170 |
Why?
|
| Haiti | 1 | 2020 | 15 | 0.170 |
Why?
|
| Epistasis, Genetic | 1 | 2021 | 44 | 0.160 |
Why?
|
| Quinolines | 1 | 2020 | 46 | 0.160 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2017 | 34 | 0.160 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 120 | 0.160 |
Why?
|
| Infant | 4 | 2018 | 1679 | 0.160 |
Why?
|
| Primaquine | 2 | 2017 | 4 | 0.160 |
Why?
|
| Young Adult | 7 | 2018 | 4772 | 0.150 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2017 | 210 | 0.150 |
Why?
|
| Sequence Deletion | 1 | 2019 | 115 | 0.150 |
Why?
|
| Fluorenes | 2 | 2016 | 13 | 0.150 |
Why?
|
| Medication Adherence | 1 | 2020 | 198 | 0.150 |
Why?
|
| Ethanolamines | 2 | 2016 | 18 | 0.150 |
Why?
|
| Drug Monitoring | 1 | 2020 | 202 | 0.140 |
Why?
|
| Alleles | 2 | 2021 | 449 | 0.140 |
Why?
|
| Computational Biology | 2 | 2024 | 366 | 0.140 |
Why?
|
| Gene Expression Regulation | 1 | 2025 | 1628 | 0.140 |
Why?
|
| Anopheles | 1 | 2018 | 23 | 0.140 |
Why?
|
| Genetic Loci | 3 | 2016 | 116 | 0.140 |
Why?
|
| Program Evaluation | 1 | 2020 | 488 | 0.140 |
Why?
|
| Polymerase Chain Reaction | 2 | 2017 | 513 | 0.130 |
Why?
|
| Transients and Migrants | 1 | 2017 | 26 | 0.130 |
Why?
|
| Transition Temperature | 1 | 2017 | 6 | 0.130 |
Why?
|
| Seasons | 2 | 2019 | 138 | 0.130 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 51 | 0.120 |
Why?
|
| Incidence | 1 | 2020 | 1410 | 0.120 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2015 | 25 | 0.120 |
Why?
|
| Point-of-Care Systems | 1 | 2017 | 126 | 0.110 |
Why?
|
| Membrane Transport Proteins | 2 | 2016 | 134 | 0.110 |
Why?
|
| Antibodies, Protozoan | 1 | 2014 | 56 | 0.110 |
Why?
|
| Antigens, Protozoan | 1 | 2014 | 63 | 0.100 |
Why?
|
| Gambia | 3 | 2019 | 6 | 0.100 |
Why?
|
| Disease Outbreaks | 1 | 2014 | 110 | 0.100 |
Why?
|
| Host-Pathogen Interactions | 1 | 2016 | 278 | 0.100 |
Why?
|
| Multilocus Sequence Typing | 1 | 2013 | 6 | 0.100 |
Why?
|
| Population Density | 1 | 2013 | 13 | 0.100 |
Why?
|
| Models, Statistical | 1 | 2015 | 309 | 0.100 |
Why?
|
| Genetic Linkage | 1 | 2013 | 93 | 0.100 |
Why?
|
| Sri Lanka | 3 | 2020 | 8 | 0.100 |
Why?
|
| Epidemics | 1 | 2013 | 27 | 0.100 |
Why?
|
| Cluster Analysis | 3 | 2022 | 261 | 0.090 |
Why?
|
| Nuclear Proteins | 1 | 2017 | 790 | 0.090 |
Why?
|
| Animals | 9 | 2025 | 21264 | 0.090 |
Why?
|
| International Cooperation | 1 | 2011 | 87 | 0.090 |
Why?
|
| Male | 8 | 2022 | 30840 | 0.080 |
Why?
|
| Adult | 6 | 2018 | 17251 | 0.080 |
Why?
|
| DNA-Binding Proteins | 1 | 2017 | 1224 | 0.080 |
Why?
|
| Research | 1 | 2011 | 194 | 0.080 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 5590 | 0.080 |
Why?
|
| Amino Acid Sequence | 3 | 2018 | 1589 | 0.080 |
Why?
|
| Molecular Epidemiology | 2 | 2022 | 31 | 0.080 |
Why?
|
| Female | 7 | 2022 | 33804 | 0.070 |
Why?
|
| Haplotypes | 3 | 2014 | 131 | 0.070 |
Why?
|
| Drug Therapy, Combination | 2 | 2020 | 460 | 0.060 |
Why?
|
| Aged | 3 | 2017 | 14882 | 0.060 |
Why?
|
| 5' Untranslated Regions | 1 | 2025 | 28 | 0.060 |
Why?
|
| Middle Aged | 3 | 2017 | 18156 | 0.060 |
Why?
|
| Polyadenylation | 1 | 2025 | 51 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2025 | 160 | 0.050 |
Why?
|
| Transcription Initiation Site | 1 | 2024 | 47 | 0.050 |
Why?
|
| Single-Cell Analysis | 1 | 2025 | 115 | 0.050 |
Why?
|
| Exons | 1 | 2024 | 205 | 0.050 |
Why?
|
| Mutation | 3 | 2017 | 2656 | 0.050 |
Why?
|
| Genetic Markers | 2 | 2015 | 126 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 1 | 2025 | 686 | 0.050 |
Why?
|
| Genome, Microbial | 1 | 2022 | 1 | 0.050 |
Why?
|
| Gene Frequency | 2 | 2015 | 121 | 0.050 |
Why?
|
| Gene Expression | 2 | 2017 | 849 | 0.040 |
Why?
|
| Sulfadoxine | 1 | 2020 | 15 | 0.040 |
Why?
|
| Genetic Fitness | 1 | 2021 | 35 | 0.040 |
Why?
|
| Family Characteristics | 1 | 2020 | 46 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2020 | 166 | 0.040 |
Why?
|
| Piperazines | 1 | 2020 | 85 | 0.040 |
Why?
|
| Nigeria | 1 | 2018 | 11 | 0.040 |
Why?
|
| Population Dynamics | 1 | 2018 | 21 | 0.040 |
Why?
|
| Burkina Faso | 1 | 2018 | 2 | 0.040 |
Why?
|
| Mosquito Vectors | 1 | 2018 | 17 | 0.030 |
Why?
|
| Evolution, Molecular | 1 | 2021 | 348 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2020 | 527 | 0.030 |
Why?
|
| Host-Parasite Interactions | 1 | 2018 | 61 | 0.030 |
Why?
|
| Animal Husbandry | 1 | 2017 | 10 | 0.030 |
Why?
|
| Cambodia | 1 | 2017 | 28 | 0.030 |
Why?
|
| Liberia | 1 | 2017 | 11 | 0.030 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2017 | 26 | 0.030 |
Why?
|
| Tanzania | 1 | 2017 | 40 | 0.030 |
Why?
|
| Fever | 1 | 2017 | 64 | 0.030 |
Why?
|
| Markov Chains | 1 | 2017 | 36 | 0.030 |
Why?
|
| Travel | 1 | 2017 | 43 | 0.030 |
Why?
|
| Mali | 1 | 2016 | 3 | 0.030 |
Why?
|
| Uganda | 1 | 2016 | 38 | 0.030 |
Why?
|
| Risk | 1 | 2017 | 371 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 2017 | 300 | 0.030 |
Why?
|
| Aotidae | 1 | 2016 | 11 | 0.030 |
Why?
|
| Parasitic Sensitivity Tests | 1 | 2016 | 14 | 0.030 |
Why?
|
| Primates | 1 | 2016 | 52 | 0.030 |
Why?
|
| Comoros | 1 | 2015 | 1 | 0.030 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2021 | 570 | 0.030 |
Why?
|
| Parasitology | 1 | 2015 | 4 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2016 | 81 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2022 | 2604 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2016 | 206 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 414 | 0.030 |
Why?
|
| South America | 1 | 2015 | 25 | 0.030 |
Why?
|
| Asia | 1 | 2015 | 25 | 0.030 |
Why?
|
| Africa | 1 | 2015 | 29 | 0.030 |
Why?
|
| Panama | 1 | 2014 | 5 | 0.030 |
Why?
|
| Colombia | 1 | 2014 | 22 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1269 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2015 | 294 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2013 | 52 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 2690 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2014 | 463 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 1979 | 0.020 |
Why?
|
| Insect Vectors | 1 | 2011 | 15 | 0.020 |
Why?
|
| Phenotype | 1 | 2016 | 1227 | 0.020 |
Why?
|
| Disease Transmission, Infectious | 1 | 2011 | 20 | 0.020 |
Why?
|
| Mefloquine | 1 | 2011 | 4 | 0.020 |
Why?
|
| Phenanthrenes | 1 | 2011 | 6 | 0.020 |
Why?
|
| Software | 1 | 2015 | 394 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2011 | 46 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2011 | 69 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 2473 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2011 | 115 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 1686 | 0.020 |
Why?
|
| Research Design | 1 | 2011 | 583 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 2274 | 0.020 |
Why?
|
| Phylogeny | 1 | 2008 | 386 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2008 | 347 | 0.020 |
Why?
|
| Time Factors | 1 | 2011 | 3748 | 0.010 |
Why?
|